Blazing a New Trail in the Treatment of Heart Disease

An injectable nanoparticle that delivers HMG-CoA reductase inhibitors, or statins, which directly inhibit atherosclerotic plaque inflammation could represent a new frontier in the treatment of heart disease. This novel approach is being developed by researchers at Icahn School of Medicine at Mount Sinai, who have seen promising results in mice models and plan to translate their findings to humans within the next few years.

Read more

A Leader in Cardiovascular Care for HIV Patients

What started as a casual observation among physicians almost a decade ago—that patients with HIV tend to develop hypertension and have a greater risk of heart attacks than the general population—has become a formal area of study and treatment within the Mount Sinai Health System.

Under the direction of Merle Myerson, MD, EdD, Director of the St. Luke’s Roosevelt Center for Cardiovascular Disease Prevention, and Director of the Cardiology Section of the Spencer Cox Center for Health, patients with HIV are being closely monitored and treated for heart disease and stroke. In fact, cardiovascular care has become increasingly critical to the overall health of HIV patients, as more of them live well into their 70s and 80s.

Read more

Novel Study Links High-Sugar Diet to Heart Disease

A novel study of high-sugar consumption in Drosophila fruit flies is leading researchers at Icahn School of Medicine at Mount Sinai to a greater understanding of diabetes-related heart disease, and to therapeutic targets that could ultimately prevent arrhythmia, fibrosis, and other serious heart conditions.

The research—led by Ross L. Cagan, PhD, Professor of Developmental and Regenerative Biology, and Associate Dean of the Graduate School of Biomedical Sciences—was conducted in partnership with scientists from the Sanford-Burnham Medical Research Institute in California, and published online in the January 10 issue of PLOS Genetics.

Read more